[Anticytosine therapy for primary myelodysplastic syndrome].
A pilot study of anticytocine therapy (PCD) was carried out in 9 patients with primary myelodysplastic syndrome (MDS). After 12 weeks, 2 patients (22%) showed hematological response cutting down the need for washed-out erythrocyte transfusions by half or more. MDS progression at different stages was reported in 4; transformation to acute myeloleukemia--2. PCD treatment is indicated in MDS patients, aged over 65, with a less than 10% blast level of the bone marrow, and without any risks of tumor progression.
Abdulkadyrov
K M
KM
Russian Research Institute of Hematology and Transfusiology, Ministry of Health of the RF, St. Peterburg.
Gritsaev
S V
SV
Bessmel'tsev
S S
SS
Martynkevich
I S
IS
Tiranova
S A
SA
Blinov
M N
MN
Osipova
R I
RI
D000368:Aged; D001853:Bone Marrow / Q000187:drug effects*; D003596:Cytosine / Q000037:antagonists & inhibitors*; D018450:Disease Progression; D017707:Erythrocyte Transfusion; D005260:Female; D006401:Hematologic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D016896:Treatment Outcome
D006401:Hematologic Agents; D003596:Cytosine